KalVista Pharmaceuticals KALV 深 沪
等待开盘 12-16 09:30:00 美东时间
16.90
-0.010
-0.06%
华盛通- 最 高17.30
- 今 开16.905
- 成交量 79.57万股
- 最 低 16.57
- 昨 收 16.91
- 总市值 8.54亿
- 52周最高 17.30
- 市盈率 静 --
- 换手率 1.57%
- 52周最低 7.30
- 委 比 97.14%
- 总股本 5054.63万
- 历史最高 45.00
- 量 比 0.79
- 振 幅 4.32%
- 历史最低 4.12
- 每 手 1
- 风险率 2.07%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅218.88%！Kyverna Therapeutics获摩根士丹利升目标价至25美元，维持"超配"评级
今日重点评级关注：摩根士丹利：维持Kyverna Therapeutics"超配"评级，目标价从20美元升至25美元；Maxim Group：维持Capricor Therapeutics"买入"评级，目标价从25美元升至50美元
12-05 08:35
Needham Reiterates Buy on KalVista Pharmaceuticals, Maintains $28 Price Target
Needham analyst Serge Belanger reiterates KalVista Pharmaceuticals (NASDAQ:KALV) with a Buy and maintains $28 price target.
12-04 18:49
Pharvaris Pill Provides Rapid Relief In Patients With Rare Swelling Attacks, Data Shows
Pharvaris reports Phase 3 data showing its oral HAE treatment delivers rapid relief, fewer second doses and strong safety results.
12-03 23:09
SA Quant ranks Goldman's small-cap stocks with largest short interest
Goldman Sachs analysts last week identified 50 small-cap stocks with the highest short interest as a percentage of market cap, a list that was topped by Anavex Life Sciences (AVXL). The brokerage look...
11-27 04:13
美股牛股 | BBAI涨超18%，分析师称收购Ask Sage将为2026年收入提供强劲助力；昂跑涨18%
BBAI涨超18%，分析师称收购Ask Sage将为2026年收入提供强劲助力；ONON涨18%，Q3净销售额7.94亿瑞士法郎高于预期，上调年度收入展望>>
11-13 14:54
KalVista Pharmaceuticals Reports Strong Q3 Results
KalVista Pharmaceuticals, Inc. ( ($KALV) ) has released its Q3 earnings. Here i...
11-12 12:12
美股大行评级 | CoreWeave、Monday遭美银、小摩等多家大行下调目标价；中金首予Nebius "跑赢大市"评级，目标价143美元
今日重点评级关注：Piper Sandler：维持MeiraGTx Hldgs"超配"评级，目标价从28美元升至30美元；RBC Capital：维持4D Molecular Therapeutics"跑赢大市"评级，目标价从26美元升至32美元
11-12 11:43
KalVista Pharma Q3 EPS $(0.92) Beats $(1.01) Estimate, Sales $13.692M Beat $4.758M Estimate
KalVista Pharma (NASDAQ:KALV) reported quarterly losses of $(0.92) per share which beat the analyst consensus estimate of $(1.01) by 9.18 percent. This is a 9.52 percent decrease over losses of $(0.84) per share from the
11-11 05:39
KalVista Pharmaceuticals Releases New Clinical And Survey Data For EKTERLY Showing It Provides Early, Effective, And Safe Treatment Of HAE Attacks In Pediatric Patients
KONFIDENT-S participants who switched to sebetralstat reported being very or extremely satisfiedInterim results from KONFIDENT-KID show sebetralstat enables early, effective, safe treatment of HAE attacks in pediatric
11-06 21:36
KalVista Pharmaceuticals Presents Data From KONFIDENT Studies On EKTERLY For Hereditary Angioedema, Highlights Need For Oral Alternatives To Injectable Therapies
Findings from KONFIDENT and KONFIDENT-S show rapid, effective treatment of HAE attacks among European participants; patient survey highlights barriers linked to injectable therapiesKalVista Pharmaceuticals, Inc.
10-07 04:03
